In addition, we bring evidence that 4-MU4-deoxy-xyloside prevented apparent fibroblast-to-myofibroblast trans-differentiation induced by TGF-β1, suggesting that inhibition of PG-GAG synthesis may provide a new therapeutic approach for IPF treatment. The gene discussed is TGFB1; the disease is idiopathic pulmonary fibrosis.